Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiovascular pharmacogenetics in the SNP era.

Journal of thrombosis and haemostasis : JTH - 1 Jul 2003

Mooser V, Waterworth D M, Isenhour T, Middleton L

Abstract excerpt

In the past pharmacological agents have contributed to a significant reduction in age-adjusted incidence of cardiovascular events. However, not all patients treated with these agents respond favorably, and some individuals may develop side-effects. With aging of the population and the growing prevalence of cardiovascular risk factors worldwide, it is expected that the demand for cardiovascular drugs will increase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genome, Human
Share to Haplotypes
Share to Linkage Disequilibrium

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Source

Identifiers

PMID: 12871273
DOI: 10.1046/j.1538-7836.2003.00272.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiovascular pharmacogenetics in the SNP era.PMID 12871273Read ↗

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).Semantic proximity Read ↗

[Cardiovascular pharmacogenomics].Semantic proximity Read ↗

Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Semantic proximity Read ↗

Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.Semantic proximity Read ↗

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.Semantic proximity Read ↗

Pharmacogenomics--10 years of progress: a cardiovascular perspective.Semantic proximity Read ↗

Cardiovascular pharmacogenomics and individualized drug therapy.Semantic proximity Read ↗

Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.Semantic proximity Read ↗

Pharmacogenomics in cardiac therapy: Personalizing treatment for heart healthSemantic proximity Read ↗

Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease.Semantic proximity Read ↗

Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.Semantic proximity Read ↗

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.